Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of DAV132 in Healthy Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy volunteers~* Normal digestive transit, with usually one daily stool.~* Females participating in the study :~must be either of non-child bearing potential (surgically sterilized at least 3 months prior to inclusion, or postmenopausal or having a negative pregnancy test and be not breastfeeding at screening, and using abstinence or a double contraception method during the treatment period and for additional period of 2 weeks after the end of investigational treatment.~* Having given and signed the written study informed consent prior to undertaking any study-related procedure.~* Covered by the French Health Insurance system.~Exclusion Criteria:~* Any history or presence of clinically relevant cardiovascular, pulmonary, gastrointestinal, hepatic, renal, metabolic, haematological, neurological, bone and joint, muscular, psychiatric, systemic, ocular, gynaecologic (if female), or infectious disease, or signs of acute illness.~* Contra-indications to fluoroquinolones, or risk factors for adverse events associated to fluoroquinolones.~* Subjects with a family history of, or actual glucose-6-phosphate dehydrogenase deficiency should be excluded.~* Subjects with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should be excluded.~* Contra-indications to DAV132, risk of gastrointestinal obstruction, perforation or haemorrhage, recent digestive tract surgery.~* Fecal colonisation by Clostridium difficile.~* Recent history of hospitalisation (within 3 months prior to inclusion).~* Any antibiotic administration within 3 months before inclusion.~* Any vaccination within the last 28 days.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Moxifloxacin (Type: ACTIVE_COMPARATOR): Moxifloxacin, oral tablets, 400mg/day, once daily 5 days
- moxifloxacin + DAV132 (Type: EXPERIMENTAL): Moxifloxacin : 400mg/day for 5 days DAV132: 7.5g x3/day for 7 days
- DAV132 (Type: EXPERIMENTAL): DAV132 oral, 7.5g x3/day for 7 days
- Negative control (Type: PLACEBO_COMPARATOR): Negative control: 7.5g x3/day for 7 days

Based on this trial design, predict the completion outcome and termination type (if applicable).